Titel
Continuous Subcutaneous Foslevodopa/Foscarbidopa
in Parkinson’s Disease: Safety and Efficacy Results
From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
Referenz
Jason Aldred et al.,
Neurol Ther 12, 1937-1958 (2023)
PDUO-DE-00010-MC
Fachrichtungen
Indikationen
Fortgeschrittener Parkinson
Parkinson
Wirkstoffe
Foscarbidopa
Foslevodopa